Oncolytics Biotech (ONCY) Stock Price, News & Analysis

Company Overview

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational form of reovirus designed to selectively target certain cancer cells and stimulate an immune response against tumors.

Oncolytics is evaluating pelareorep in combination with other cancer treatments, including immune checkpoint inhibitors and chemotherapy. Its research has focused primarily on breast cancer, pancreatic cancer and other solid tumors, with development programs conducted through collaborations and clinical studies in North America and other regions.

Founded in 1998 and headquartered in Calgary, Alberta, Oncolytics Biotech operates as a development-stage biotechnology company. Pelareorep has not been approved for commercial sale, and the company’s programs remain subject to clinical, regulatory and other development requirements.

Key Stats

• Today's Range: $0.62 to $0.65
• 50-Day Range: $0.63 to $0.88
• 52-Week Range: $0.62 to $1.42
• Volume: 609,209 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $80.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Oncolytics Biotech Stock Analysis - MarketRank™

Oncolytics Biotech scored higher than 44% of companies evaluated by MarketBeat, and ranked 583rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oncolytics Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Oncolytics Biotech has a consensus price target of $5.00, representing about 692.4% upside from its current price of $0.63.

Amount of Analyst Coverage

Oncolytics Biotech has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncolytics Biotech are expected to grow in the coming year, from ($0.29) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncolytics Biotech is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncolytics Biotech is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.79% of the float of Oncolytics Biotech has been sold short.

Short Interest Ratio / Days to Cover

Oncolytics Biotech has a short interest ratio ("days to cover") of 7.23.

Change versus previous month

Short interest in Oncolytics Biotech has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncolytics Biotech does not currently pay a dividend.

Dividend Growth

Oncolytics Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.11

News Sentiment

Oncolytics Biotech has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Oncolytics Biotech this week, compared to 3 articles on an average week.

Search Interest

12 people have searched for ONCY on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.

MarketBeat Follows

12 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.10% of the stock of Oncolytics Biotech is held by insiders.

Percentage Held by Institutions

6.82% of the stock of Oncolytics Biotech is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ONCY
• CIK: 1129928
• Web: www.oncolyticsbiotech.com
• Phone: (403) 670-7377
• Fax: 403-283-0858
• Employees: 29
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Oncolytics Biotech: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +692.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.76 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -442.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.35
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -15.78

Miscellaneous

• Outstanding Shares: 127,510,000
• Free Float: 127,383,000
• Market Cap: $80.46 million
• Optionable: Not Optionable
• Beta: 1.15